These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21491807)

  • 21. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delegations of authority and organization; National Childhood Vaccine Injury Act of 1986--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17105-6. PubMed ID: 10125232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Financial disclosure by clinical investigators--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(21):5233-54. PubMed ID: 10177332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard Preparations, Limits of Potency, and Dating Period Limitations for Biological Products. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 May; 81(86):26687-92. PubMed ID: 27192727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license; correction--FDA. Proposed rule; correction.
    Fed Regist; 1998 Sep; 63(170):46718. PubMed ID: 10182705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Administrative practices and procedures; internal review of agency decisions---FDA. Direct final rule.
    Fed Regist; 1998 Jun; 63(115):32733-5. PubMed ID: 10180278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premarket notifications of new dietary ingredients--a ten-year review.
    McGuffin M; Young AL
    Food Drug Law J; 2004; 59(2):229-44. PubMed ID: 15318394
    [No Abstract]   [Full Text] [Related]  

  • 39. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administrative practices and procedures; internal agency review of decisions; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(115):32772-4. PubMed ID: 10180279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.